Want to see ES:ALM full AI Analyst Report?
ALM Stock Chart & Stats
€10.40
€0.12(1.07%)
At close: 4:00 PM EDT
€10.40
€0.12(1.07%)
Day’s Range― - ―
52-Week Range€10.02 - €13.98
Previous CloseN/A
Volume17.72K
Average Volume (3M)122.64K
Market Cap
€2.31B
Enterprise Value€2.41K
Total Cash (Recent Filing)€355.41M
Total Debt (Recent Filing)€363.67M
Price to Earnings (P/E)31.5
Beta0.63
Next Earnings
Nov 09, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend Yield1.76%
Share Statistics
EPS (TTM)0.33
Shares Outstanding217,777,330
10 Day Avg. Volume134,370
30 Day Avg. Volume122,637
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)1.85
Price to Sales (P/S)2.49
P/FCF Ratio20.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.39
Revenue Forecast (FY)€1.23B
Bulls Say, Bears Say
Bulls Say
Specialized Dermatology PlatformA focused medical-dermatology portfolio gives Almirall specialized commercial expertise and a clear market identity. Branded prescription products can support recurring demand across established geographies, while the European footprint provides a platform for broader product adoption and lifecycle expansion.
Revenue And Profitability ReboundThe TTM rebound shows materially stronger operating performance, combining rapid revenue growth with renewed profitability and solid reported margins. If the improvement persists, higher earnings can strengthen internal funding, support commercial investment, and improve the company’s ability to compound results.
Conservative Improving LeverageLower leverage and a growing equity base provide financial resilience and greater flexibility for product development, partnerships, and commercial investment. A conservative balance sheet also reduces the strain of financing obligations, helping Almirall absorb operating volatility while pursuing longer-term growth.
Bears Say
Earnings Durability Remains UncertainThe latest recovery is encouraging, but the history of losses, weak earnings, and only mid-single-digit returns on capital indicates that profitability has not yet been consistently normalized. This volatility makes future earnings power less dependable and may limit the efficiency of reinvestment.
Inconsistent Cash-flow HistoryStrong TTM operating and free cash flow is offset by a recent history of inconsistent conversion, including negative or breakeven periods. Uneven cash generation can constrain dependable self-funding for research, launches, and business development, even when accounting profits improve.
Cash Conversion Is Not Uniformly StrongThe TTM cash outcome is solid, but free cash flow below net income and coverage below one indicate that reported earnings do not convert fully and consistently into operating cash under the provided metrics. Persistent conversion weakness could reduce financial flexibility and earnings quality.
Almirall News
ALM FAQ
What was Almirall SA’s price range in the past 12 months?
Almirall SA lowest stock price was €10.02 and its highest was €13.98 in the past 12 months.
What is Almirall SA’s market cap?
Almirall SA’s market cap is €2.31B.
When is Almirall SA’s upcoming earnings report date?
Almirall SA’s upcoming earnings report date is Nov 09, 2026 which is in 51 days.
How were Almirall SA’s earnings last quarter?
Almirall SA released its earnings results on Jul 24, 2026. The company reported €0.112 earnings per share for the quarter, missing the consensus estimate of €0.13 by -€0.018.
Is Almirall SA overvalued?
According to Wall Street analysts Almirall SA’s price is currently Overvalued.
Does Almirall SA pay dividends?
Almirall SA pays a Annually dividend of €0.184 which represents an annual dividend yield of 1.76%. See more information on Almirall SA dividends here
What is Almirall SA’s EPS estimate?
Almirall SA’s EPS estimate is 0.13.
How many shares outstanding does Almirall SA have?
Almirall SA has 217,777,330 shares outstanding.
What happened to Almirall SA’s price movement after its last earnings report?
Almirall SA reported an EPS of €0.112 in its last earnings report, missing expectations of €0.13. Following the earnings report the stock price went up 1.266%.
Which hedge fund is a major shareholder of Almirall SA?
Currently, no hedge funds are holding shares in ES:ALM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Almirall Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.86%
12-Months-Change
Fundamentals
Return on Equity
1.76%
Trailing 12-Months
Asset Growth
2.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Almirall SA
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.